Semax / Selank blend
Pre-mixed lyophilised combination of Semax and Selank (10 mg + 10 mg per vial), for comparative neuropeptide research.
Prepared to order · approx. 7 days + Royal Mail Tracked 24
SKU BP-SXSK-20 · ≥99% (see COA) · Lyophilised powder
Note: Component ratio taken from the supplier list ("Semax 10mg+Selank 10mg"). Confirm the per-component content from the batch COA.
Semax / Selank blend overview
Each vial contains Semax 10 mg and Selank 10 mg (20 mg total peptide), co-lyophilised, per the supplier specification. See the individual Semax and Selank pages for component data. Supplied for in-vitro laboratory research only.
Semax / Selank blend research background
Evidence status: This combination has not been studied as a blend; findings summarised here relate to the individual components, much of it preclinical (cell or animal) or small-scale. They are not established effects in humans, have not been evaluated by the MHRA, and are provided for scientific context only. This product is supplied strictly for laboratory research and is not for human or veterinary use.
Established research
Peer-reviewed published findings, with referencesOverview & discovery history
- This research blend combines 2 separately characterised compounds. The combination itself has not been studied in peer-reviewed research; the summaries below relate to each component individually. See each component's own product page for its full research background.
Chemical identity
Identity values are confirmed per lot on the certificate of analysis. Salt/counter-ion form (e.g. acetate or TFA) is stated on the COA where applicable.
Mechanisms investigated
Research areas & model types
Human clinical research status
- No studies of this combination were identified. Clinical-status notes for individual components are summarised below; they do not apply to the blend.
- Semax: Clinical studies of Semax in ischaemic stroke have been published in Russian journals [6][7]. Semax is not authorised as a medicine in the UK, the EU or the US.
- Selank: A Russian clinical study compared Selank with medazepam [8]. Selank is not authorised as a medicine in the UK, the EU or the US.
Safety observations reported in studies
- No safety data exist for the combination. Interactions between components have not been studied.
Known limitations
- The combination has not been studied; whether the components interact chemically or biologically in solution is unknown.
Storage & handling for laboratory use
Store at −20 °C. Protect from light.
Store lyophilised material sealed at −20 °C or below, protected from light and moisture. Allow the vial to equilibrate to room temperature before opening to limit condensation.
- Allow the sealed vial to reach room temperature before opening to limit condensation.
- Any solutions should be prepared only for in-vitro laboratory work under your own validated protocol; aliquoting limits repeated freeze–thaw cycles.
- Handle with standard laboratory PPE in line with your risk assessment and the Safety Data Sheet (SDS). Britpep does not provide preparation or administration guidance.
Emerging & theoretical
Unconfirmed — hypotheses & ongoing researchThese are unconfirmed hypotheses and early-stage lines of enquiry, not established effects. Not evaluated by the MHRA. Not for human or veterinary use.
Hypotheses proposed by researchers
- Semax: Researchers have proposed that Semax's effects are mediated in part by modulating neurotrophin (BDNF/TrkB) expression [1][9].
- Selank: Researchers have proposed that Selank acts as a positive allosteric modulator of GABA-A receptors [3].
Open scientific questions
- Whether the components are chemically compatible and stable when combined has not been reported.
Preprints: none included (no relevant preprint could be verified). Anecdotal, user-reported or social-media material is deliberately excluded.
References
- Dolotov OV, Karpenko EA, Seredenina TS et al.. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006. PubMed 16635254 · doi:10.1111/j.1471-4159.2006.03658.x
- Eremin KO, Kudrin VS, Saransaari P et al.. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005. PubMed 16362768 · doi:10.1007/s11064-005-8826-8
- Vyunova TV, Andreeva L, Shevchenko K et al.. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018. PubMed 30255741 · doi:10.2174/0929866525666180925144642
- Kozlovskaya MM, Kozlovskii II, Val'dman EA et al.. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci Behav Physiol. 2003. PubMed 14969422 · doi:10.1023/a:1025988519919
- Volkova A, Shadrina M, Kolomin T et al.. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016. PubMed 26924987 · doi:10.3389/fphar.2016.00031
- Gusev EI, Martynov MY, Kostenko EV et al.. [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PubMed 29798983 · doi:10.17116/jnevro20181183261-68
- Gusev EI, Skvortsova VI, Miasoedov NF et al.. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zh Nevrol Psikhiatr Im S S Korsakova. 1997. PubMed 11517472
- Zozulia AA, Neznamov GG, Siuniakov TS et al.. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PubMed 18454096
- Dmitrieva VG, Povarova OV, Skvortsova VI et al.. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010. PubMed 19633950 · doi:10.1007/s10571-009-9432-0
- Medvedeva EV, Dmitrieva VG, Povarova OV et al.. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014. PubMed 24661604 · doi:10.1186/1471-2164-15-228
- Sudarkina OY, Filippenkov IB, Stavchansky VV et al.. Brain Protein Expression Profile Confirms the Protective Effect of the ACTH((4-7))PGP Peptide (Semax) in a Rat Model of Cerebral Ischemia-Reperfusion. Int J Mol Sci. 2021. PubMed 34201112 · doi:10.3390/ijms22126179
- Filatova E, Kasian A, Kolomin T et al.. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol. 2017. PubMed 28293190 · doi:10.3389/fphar.2017.00089
- Kasian A, Kolomin T, Andreeva L et al.. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017. PubMed 28280289 · doi:10.1155/2017/5091027
Every reference was checked against PubMed (NCBI) before publication. Summaries describe published research only and are not claims of any effect in humans or animals.
Certificates of analysis
[No batch COA published yet. The certificate for each lot will be listed here and in the COA checker before release.]
Related research compounds
Browse similar compounds: Neuropeptide research peptides, Research peptide blends or the full catalogue.